Review
Open access
Sep 2026
Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.
Overall, mono- and dual-incretin agonist therapies represent a significant advance in the treatment landscape of MASLD/MASH, although long-term outcome data are required to confirm durability, safety, and impact on major adverse liver-related outcomes.
S. Chirapongsathorn, F. Tacke
· Digestion · 0 citations